<DOC>
	<DOCNO>NCT00933816</DOCNO>
	<brief_summary>The purpose study determine recommend dose combination therapy sorafenib hepatic arterial infusion low dose cisplatin fluorouracil patient advance hepatocellular carcinoma ( Phase I ) , evaluate efficacy combination therapy recommend dose ( Phase II ) .</brief_summary>
	<brief_title>Study Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin ( FP ) Intraarterial Infusion Chemotherapy</brief_title>
	<detailed_description>In Phase I , 9 18 patient enrol . Cohorts 3 6 patient receive escalate dose cisplatin fluorouracil MTD reach . There intra-patient dose escalation . Sorafenib administer orally dose 400mg bid 28 day patient . Cisplatin dose 10-20mg/m2 administer day 1 day8 , fluorouracil dose 170-330mg/m2 administer continuously day1-day5 , day8-day12 via implant catheter system . A cycle define 28 day 3 cycle combination therapy continue . At end cycle , adverse effect evaluate dose escalation determine . In Phase II , 28 patient enrol . Time progression combination therapy recommend dose evaluate .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . 20 Years old . 2 . Life expectancy least 12 week pretreatment evaluation . 3 . Advanced hepatocellular carcinoma histological evidence biopsy specimen , typical finding dynamic CT CT hepatic arteriography/arterioportography . 4 . Not suitable resection local ablation therapy transcatheter arterial chemoembolization . 5 . One treatment hepatic arterial infusion chemotherapy without implant catheter system allow . 6 . ECOG Performance status 0 1 . 7 . Cirrhotic status ChildPugh class A B . 8 . Adequate bone marrow , liver renal function , assess follow laboratory requirement : Hemoglobin 8.5 g/dl Granulocytes 1500/μL Platelet count 50,000 /μL PTINR 2.3 PT 6 second control Total serum bilirubin 2 mg/dl AST ( SGOT ) ALT ( SGPT ) 5 × upper limit normal Serum creatinine 1.5 × upper limit normal Amylase 5 × upper limit normal 9 . Written Informed Consent must obtain . 1 . Previous malignancy ( except cervical carcinoma situ , adequate treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis T1 ] , early gastric cancer , malignancy curatively treat &gt; 3 year prior entry 2 . Renal failure 3 . Any heart disease follow Congestive heart failure define NYHA class III IV Active coronary artery disease ischemic heart disease cardiac infarction within 6 month prior screen Serious cardiac arrhythmia Serious hypertension 4 . Active clinically serious infection . 5 . Active chicken pox . 6 . Auditory disorder . 7 . Known history HIV infection . 8 . Known metastatic meningeal tumor . 9 . Extrahepatic tumor spread . 10 . History seizure disorder . 11 . Clinically significant gastrointestinal bleeding within 4 week prior study entry . 12 . Embolization infarction transient ischemic disease , deep vein thrombosis , pulmonary embolization ) . 13 . Any history treatment follow : Treatment agent induces CYP3A4 Surgical procedure within 4 week prior start study drug History organ allograft 14 . Patients unable swallow oral medication . 15 . Gastrointestinal disease may affect absorption drug pharmacokinetics . 16 . Medication may affect absorption drug pharmacokinetics . 17 . Any disease disorder may affect evaluation study drug . 18 . Entry clinical trial within 4 week prior entry study . 19 . Pregnant breastfeeding patient . 20 . Known allergy investigational agent agent give association trial . 21 . Substance abuse , medical , psychological social condition , judgment investigator , likely interfere patient 's participation study evaluation stuy result . 22 . Any condition unstable could jeopardize safety patient compliance study , investigator 's judgment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>sorafenib</keyword>
	<keyword>intraarterial infusion chemotherapy</keyword>
	<keyword>Low dose FP</keyword>
	<keyword>cisplatin</keyword>
	<keyword>fluorouracil</keyword>
</DOC>